Results for tag: "Synagis"

Synagis is a vaccine used to prevent severe respiratory illness caused by respiratory syncytial virus (RSV) in infants and young children. It is the only approved monoclonal antibody for the prevention of RSV disease in high-risk infants. Synagis is administered as a series of monthly injections during the RSV season, which typically runs from November to March in the United States. Synagis is a niche market within the larger vaccine industry. It is primarily used to protect infants and young children who are at high risk of developing severe RSV disease. These high-risk infants include those born prematurely, those with chronic lung disease, and those with weakened immune systems. The Synagis market is dominated by a few large pharmaceutical companies, including AstraZeneca, GlaxoSmithKline, Merck, and Novartis. Other companies, such as AbbVie, Pfizer, and Sanofi, also have a presence in the market. Show Less Read more